Show simple item record

dc.contributor.authorLøes, Inger Marieeng
dc.contributor.authorImmervoll, Heikeeng
dc.contributor.authorAngelsen, Jon-Helgeeng
dc.contributor.authorHorn, Arildeng
dc.contributor.authorGeisler, Jürgeneng
dc.contributor.authorBusch, Christianeng
dc.contributor.authorLønning, Per Eysteineng
dc.contributor.authorKnappskog, Stianeng
dc.date.accessioned2015-09-08T12:32:34Z
dc.date.available2015-09-08T12:32:34Z
dc.date.issued2015-02
dc.identifier.issn1010-4283
dc.identifier.urihttp://hdl.handle.net/1956/10434
dc.description.abstractPersonalized cancer care requires reliable biomarkers. While the BRAF V600E mutation is implemented in the clinic, no method for its detection has so far been established as reference. We aimed to perform a comprehensive comparison of three methods currently being used for V600E detection in clinical samples. We analysed genomic DNA from 127 malignant melanomas (77 patients) and 389 tumours from 141 colorectal cancer patients (383 liver metastases and 6 primary tumours) by Sanger sequencing and a single probe-based high-resolution melting assay (LightMix). Formalin-fixed paraffin-embedded (FFPE) tissue from a subset of these lesions (n = 77 and 304, respectively) was analysed by immunohistochemistry (IHC) using the V600E-specific antibody VE1. In a dilution series of V600E-mutated DNA in wild-type DNA, the detection limit for the LightMix assay was 1:1000 mutated alleles while it was 1:10 for Sanger sequencing. In line with this, we detected 15 additional mutated melanoma samples and two additional mutated metastatic colorectal cancer samples by the LightMix assay compared to Sanger sequencing. For the melanoma samples, we observed high concordance between DNA-based methods and analysis by IHC. However, in colorectal samples, IHC performed poorly with 12 samples being scored as V600E positive exclusively by IHC and nine samples being scored as V600E negative exclusively by IHC. In conclusion, the VE1 antibody is not recommendable for clinical tests of colorectal cancer samples. For melanoma samples, IHC may be useful as a screening tool guiding further analytical approaches.eng
dc.language.isoengeng
dc.publisherSpringereng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.subjectBRAF mutationseng
dc.subjectDetection methodseng
dc.subjectImmunohistochemistryeng
dc.subjectColorectal cancereng
dc.subjectMalignant melanomaeng
dc.titlePerformance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimeneng
dc.typeJournal articleeng
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Oncology: 762
dc.date.updated2015-06-29T08:45:14Z
dc.rights.holderCopyright 2014 The Authorseng
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
bora.journalTitleTumour Biologyeng
bibo.volume36eng
bibo.issue2eng
bibo.pageStart1003eng
bibo.pageEnd1013eng
dc.type.documentJournal article
dc.identifier.cristinID1196481
dc.identifier.cristinID1196481eng
dc.identifier.doi10.1007/s13277-014-2711-5
dc.source.issn1010-4283
bora.bpoaIDbpoa266


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY